Company intelligence / Profile preview
InnoMedica
Bern, Switzerlandinnomedica.com ↗
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
The company has treated 43 cancer patients and 21 Parkinson's patients in clinical trials. For Parkinson's disease, they have demonstrated remarkable results including crossing the blood-brain barrier, offering sustained symptom improvement and halting disease progression. In cancer therapy, their lipid nanoparticles significantly reduce side effects while increasing efficacy[2][5][6].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Nanoparticle drug delivery systemLiposomal technology
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
International and national research collaborations
Beyond the preview
Go deeper on InnoMedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoMedica.